Neoplasms

All Conditions

Rare Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor

Neuroepithelioma

All Drugs and Chemicals

Somatostatin

Lutetium Lu 177 dotatate

Radiopharmaceuticals

Treated per labeled LUTATHERA dosing regimen.

Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.

LUTATHERA

Study Director

Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).

To assess the incidence and nature of potential long-term safety outcomes in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. Retrospective and prospective data will be used.

Post-Authorization Long-Term Safety Study of LUTATHERA

International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours

Advanced Accelerator Applications

Digestive System Diseases

Gland and Hormone Related Diseases

Behaviors and Mental Disorders

Intestinal Neoplasms

Pancreatic Neoplasms

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Stomach Diseases

Quality of Life

Oculocerebral Syndrome With Hypopigmentation

Pancreatic Cancer

Stomach Cancer

Ipsen Medical Director

Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

SOMATOSTATIN TREATMENT EXPERIENCE TRIAL An Observational Cross Sectional Trial Investigating Quality of Life, Treatment Experience and Direct Cost of Treatment With Somatostatin Analogues in Subjects With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS)

Subject questionnaire asks "In your opinion, how did the last injection go?", subject chooses either 'no problems' or 'problems occurred'.

Mean physical health score and mean mental health score in SF-12 derived according to the SF-12 manual

Subjects asked "To what extent do you feel anxiety before the injection?"

Ipsen

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Post-Authorization Long-Term Safety Study of LUTATHERA	NCT03691064	Neuroendocrine ...	LUTATHERA	18 Years -	Advanced Accelerator Applications
Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours	NCT02788565	Gastroenteropan...		18 Years -	Ipsen
Post-Authorization Long-Term Safety Study of LUTATHERA	NCT03691064	Neuroendocrine ...	LUTATHERA	18 Years -	Advanced Accelerator Applications

Spots Global Cancer Trial Database for gastroenteropancreatic neuroendocrine tumours